Galveston, TX, United States of America

Bruce A Luxon

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: The University of Texas System, Mei Technologies, Inc.. Active years: 2005-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bruce A Luxon. Retrieved from https://idiyas.com/inventor/bruce-a-luxon-df7ysiq6

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 50.0

 


Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 149(Granted Patents)


Company Filing History:


Years Active: 2005-2017

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations by Bruce A. Luxon: Pioneering Patents in Biotechnology

Introduction

Bruce A. Luxon, an accomplished inventor based in Galveston, Texas, has made significant contributions to the field of biotechnology. With a total of six patents to his name, his work primarily focuses on the development of advanced therapeutic techniques and diagnostic methods that leverage oligonucleotides.

Latest Patents

Among his most significant patents is the invention focused on "Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors." This innovative approach includes compositions and methods for creating a combinatorial library aimed at identifying modified thioaptamers that can bind to crucial transcription factors such as IL-6, NF-κB, and AP-1. This invention further extends to treatments for viral infections and methods of enhancing host immune responses through vaccines and adjuvants.

Another noteworthy patent addresses "Methods for detecting, diagnosing and treating human renal cell carcinoma." This invention utilizes gene expression profiling and hierarchical clustering analysis to identify differential gene expressions in both normal renal epithelial cells and renal cell carcinomas. The identified genes are instrumental in enhancing diagnostic, prognostic, and targeted therapeutic strategies for renal cell carcinoma treatment.

Career Highlights

Bruce A. Luxon has accumulated extensive experience through his career, significantly impacting the biotechnology sector. He has collaborated with renowned institutions such as the University of Texas System and Mei Technologies, Inc., where he has honed his skills as a leading researcher and inventor.

Collaborations

Throughout his career, Luxon has worked alongside notable colleagues, including David G. Gorenstein and Norbert Herzog. Their collaborations have been pivotal in advancing various projects, fostering a creative environment that promotes innovative solutions to complex biomedical challenges.

Conclusion

In summary, Bruce A. Luxon's contributions through his patents reveal a dedication to addressing critical health issues through innovative biotechnological solutions. His work not only reflects his ingenuity as an inventor but also underscores the potential impact of his inventions on the fields of diagnostics and therapeutic treatments. With his ongoing efforts, Luxon continues to pave the way for advancements in biotechnology, showcasing the importance of innovation in improving healthcare outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…